Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Emily Bernstein

Showing results (51-60 of 87) with videos related to

Pageof 9
Sort By:
Cell Reports|June 2, 2023
5-Azacytidine- and retinoic-acid-induced reprogramming of DCCs into dormancy suppresses metastasis via restored TGF-β-SMAD4 signalingDeepak K Singh, Saul Carcamo, Eduardo F Farias, et al.
Nature Communications|March 7, 2013
MacroH2A histone variants act as a barrier upon reprogramming towards pluripotencyAlexandre Gaspar-Maia, Zulekha A Qadeer, Dan Hasson, et al.
Cell Reports|June 28, 2016
Cbx8 Acts Non-canonically with Wdr5 to Promote Mammary TumorigenesisChi-Yeh Chung, Zhen Sun, Gavriel Mullokandov, et al.
Cell|April 12, 2011
Wdr5 mediates self-renewal and reprogramming via the embryonic stem cell core transcriptional networkYen-Sin Ang, Su-Yi Tsai, Dung-Fang Lee, et al.
Genes & Development|March 7, 2012
ATRX-mediated chromatin association of histone variant macroH2A1 regulates α-globin expressionKajan Ratnakumar, Luis F Duarte, Gary LeRoy, et al.
Nature|December 24, 2010
The histone variant macroH2A suppresses melanoma progression through regulation of CDK8Avnish Kapoor, Matthew S Goldberg, Lara K Cumberland, et al.
JCI Insight|February 6, 2024
Differential histone acetylation and super-enhancer regulation underlie melanoma cell dedifferentiationKaren Mendelson, Tiphaine C Martin, Christie B Nguyen, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|June 30, 2022
Early versus delayed treatment with glatiramer acetate: Analysis of up to 27 years of continuous follow-up in a US open-label extension studyCorey C Ford, Jeffrey A Cohen, Andrew D Goodman, et al.
Nature Communications|January 31, 2015
NR2F1 controls tumour cell dormancy via SOX9- and RARβ-driven quiescence programmesMaria Soledad Sosa, Falguni Parikh, Alexandre Gaspar Maia, et al.
Cell Reports|April 6, 2022
Altered BAF occupancy and transcription factor dynamics in PBAF-deficient melanomaSaul Carcamo, Christie B Nguyen, Elena Grossi, et al.
Pageof 9

Showing results (51-60 of 87) with videos related to

Sort By:
Pageof 9
Cell Reports|June 2, 2023
5-Azacytidine- and retinoic-acid-induced reprogramming of DCCs into dormancy suppresses metastasis via restored TGF-β-SMAD4 signalingDeepak K Singh, Saul Carcamo, Eduardo F Farias, et al.
Nature Communications|March 7, 2013
MacroH2A histone variants act as a barrier upon reprogramming towards pluripotencyAlexandre Gaspar-Maia, Zulekha A Qadeer, Dan Hasson, et al.
Cell Reports|June 28, 2016
Cbx8 Acts Non-canonically with Wdr5 to Promote Mammary TumorigenesisChi-Yeh Chung, Zhen Sun, Gavriel Mullokandov, et al.
Cell|April 12, 2011
Wdr5 mediates self-renewal and reprogramming via the embryonic stem cell core transcriptional networkYen-Sin Ang, Su-Yi Tsai, Dung-Fang Lee, et al.
Genes & Development|March 7, 2012
ATRX-mediated chromatin association of histone variant macroH2A1 regulates α-globin expressionKajan Ratnakumar, Luis F Duarte, Gary LeRoy, et al.
Nature|December 24, 2010
The histone variant macroH2A suppresses melanoma progression through regulation of CDK8Avnish Kapoor, Matthew S Goldberg, Lara K Cumberland, et al.
JCI Insight|February 6, 2024
Differential histone acetylation and super-enhancer regulation underlie melanoma cell dedifferentiationKaren Mendelson, Tiphaine C Martin, Christie B Nguyen, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|June 30, 2022
Early versus delayed treatment with glatiramer acetate: Analysis of up to 27 years of continuous follow-up in a US open-label extension studyCorey C Ford, Jeffrey A Cohen, Andrew D Goodman, et al.
Nature Communications|January 31, 2015
NR2F1 controls tumour cell dormancy via SOX9- and RARβ-driven quiescence programmesMaria Soledad Sosa, Falguni Parikh, Alexandre Gaspar Maia, et al.
Cell Reports|April 6, 2022
Altered BAF occupancy and transcription factor dynamics in PBAF-deficient melanomaSaul Carcamo, Christie B Nguyen, Elena Grossi, et al.
Pageof 9